Imaging Diagnostic Systems Sells CTLM System in Malaysia

Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) a pioneer in laser optical breast imaging systems, announced today the sale of another CT Laser Mammography system in Asia. The system, which was sold to and installed at the Katherine Women's Health Center in Malaysia, is currently being used in patient examinations. The Women's Health Center will also serve as a training and demonstration site for future customers.

"We are getting very positive responses whenever we introduce the use of CTLM and believe that the CTLM will do very well in Malaysia and Brunei," commented Christopher Su, Director of Daichi Holding Berhad, IDSI's Malaysian agents.

The CTLM system was sold through Daichi Holding Berhad. The transaction was completed with the full balance wired to IDSI the week of September 14th. Daichi Holding Berhad is a equipment distributor with several years of experience serving as a representative for many companies and products.

"The first CTLM in Southeast Asia will not only introduce this new technology to the general public, but will also allow technologists, radiologists, and service engineers to become familiar with this emerging technology through the in-house training center," stated Arthur Su, President of Daichi Holding Berhad. "This exposure will open the door for future CTLM sales in this region."

About Imaging Diagnostic Systems, Inc.

Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM(R) system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM(R)) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.

The Company is currently engaged in collecting clinical data to support the Premarket approval application for marketing clearance in the U.S. The FDA has determined that the Company's clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States.

For more information, visit our website: www.imds.com

As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

SOURCE: Imaging Diagnostic Systems, Inc.

Imaging Diagnostic Systems, Inc. 
Deborah O'Brien, 954-257-8940

Related terms: asia, brunei, clinical, computer, connecticut, distributor, federal, health, law, malaysia, marketing, optical, president, products, sales, securities, technology, training, united states, women